Somewhat Positive Media Coverage Likely to Affect Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price
Media stories about Oramed Pharmaceuticals (NASDAQ:ORMP) have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oramed Pharmaceuticals earned a news impact score of 0.12 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 66 out of 100, indicating that recent news coverage is likely to have an effect on the company’s share price in the near term.
Shares of Oramed Pharmaceuticals (NASDAQ:ORMP) traded up 0.12% during trading on Friday, reaching $8.04. 11,792 shares of the company were exchanged. The firm’s market capitalization is $107.09 million. The company’s 50-day moving average is $8.01 and its 200 day moving average is $7.14. Oramed Pharmaceuticals has a 1-year low of $5.70 and a 1-year high of $9.17.
Separately, HC Wainwright set a $25.00 price objective on shares of Oramed Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, May 22nd.
COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/07/somewhat-positive-press-coverage-likely-to-impact-oramed-pharmaceuticals-nasdaqormp-share-price-updated-updated-updated.html.
In related news, Director Xiaopeng Li purchased 89,636 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average price of $8.50 per share, for a total transaction of $761,906.00. Following the acquisition, the director now directly owns 206,350 shares of the company’s stock, valued at approximately $1,753,975. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 25.90% of the company’s stock.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Stock Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.